Drugs / pavurutamab
pavurutamab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04998747 | Aug 2023 → Aug 2025 | refractory plasma cell neoplasm | Amgen | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT03287908 | Nov 2017 → Jun 2023 | refractory plasma cell neoplasm | Amgen | Terminated | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| — | NCT05256446 Background | — | — | Amgen | No longer available | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-12-05 | Amgen | Results Amgen To Present First Clinical Data For BCMA-Targeted Half-Life Extended BiTE® Therapy AMG 701 At ASH 2020 amgen.com ↗
The response rate was 36% at doses of 3-18 mg with responses lasting up to 26 months in one patient. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-12-05 | Amgen | Amgen To Present First Clinical Data For BCMA-Targeted Half-Life Extended BiTE® Therapy AMG 701 At ASH 2020 amgen.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pavurutamab | “The B-cell maturation antigen (BCMA)-targeting bispecific T-cell engager pavurutamab (AMG 701) directs the cytotoxic T-cell response toward multiple myeloma (MM) cells.” PMID 41950113 ↗ Jul 2026 |
| Known as | AMG 701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04998747 ↗ |
| Known as | Anti-bcma x anti-cd3 bite amg 701 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650255 ↗ |
| Modality | Protein / enzyme biologic | “bispecific T-cell engager molecule AMG 701” PMID 32898244 ↗ Sep 2020 |
| Route | Intravenous | “Subjects will receive IV infusions of AMG 701.” NCT03287908 ↗ |